AUS
NZ
UK
CA
USA
IND
Healthcare
Race Oncology Advances Cancer Research with G-Quadruplex Expertise
October 09, 2025 02:23 PM AEDT| By SamRace Oncology (ASX:RAC) strengthens its drug development strategy by appointing a G4-DNA pioneer to its advisory board and confirming its lead drug’s anticancer mechanism.
Sonic Healthcare (ASX:SHL): Key Insights in Healthcare Sector
October 08, 2025 12:52 PM AEDT| By SamThis article provides a comprehensive analysis of Sonic Healthcare (ASX:SHL), exploring its global operations, healthcare services, market position, and growth potential within the ASX stock market.
Race Oncology (ASX:RAC) Unveils Novel (E,E)-Bisantrene Pathway
October 06, 2025 04:10 PM AEDT| By SamRace Oncology (ASX:RAC) hosts a webinar to discuss the groundbreaking mechanism of (E,E)-bisantrene, highlighting its role in cancer therapeutics and future clinical strategies.
Unlocking CSL Share Insights: Key Metrics and Market Dynamics
October 06, 2025 03:26 PM AEDT| By SamExplore CSL Ltd (ASX:CSL) share performance, financial health, and market dynamics with insights into revenue, profit, and key business units.
Race Oncology (ASX:RAC) Advances Breakthrough Cancer Therapy
October 03, 2025 02:14 PM AEST| By SamThis article explores Race Oncology Ltd's (ASX:RAC) recent discovery of a novel mechanism of action for its lead drug candidate, (E,E)-bisantrene, highlighting its potential impact on cancer treatment strategies.
Artrya Limited’s New ASX Securities Quotation Sparks Market Focus
October 03, 2025 02:14 PM AEST| By SamArtrya Limited (ASX:AYA) has announced the quotation of new securities on the ASX, highlighting its role in advancing cardiovascular diagnostics and strengthening innovation within the broader Australian stock market.
Exploring ASX 200 Penny Stocks: EZZ Life Science Holdings and Key Market Movers
October 03, 2025 02:05 PM AEST| By SamAustralia’s penny stocks spotlight resilience and growth, featuring EZZ Life Science Holdings, Alfabs Australia, and Dusk Group. These companies showcase diverse opportunities across health, retail, engineering, and resources in the ASX market.
Paradigm Biopharmaceuticals Sparks Investor Curiosity in ASX 200
October 01, 2025 02:01 PM AEST| By SamParadigm Biopharmaceuticals (ASX:PAR) advances Phase 3 trials for osteoarthritis treatment, highlighting biotechnology innovation and potential growth opportunities within the ASX stock market beyond traditional mining and industrial sectors.
EVE Health Launches Dyspro for Patients, ASX 200 Spotlight
October 01, 2025 11:17 AM AEST| By SamEVE Health (ASX:EVE) launches Dyspro prescriptions in Australia and introduces Reclaim My Cycle, enhancing patient support and clinical adoption in women’s health.
Orthocell Expands to Canada with Remplir Nerve Wrap Launch
September 30, 2025 03:19 PM AEST| By SamOrthocell (ASX:OCC) strengthens global presence with Canadian distributor for Remplir, advancing international nerve repair solutions while aligning with opportunities across ASX markets.
Starpharma & Radiopharm Transform Cancer Therapies in ASX 200
September 30, 2025 12:32 PM AEST| By SamStarpharma (ASX:SPL) teams up with Radiopharm Theranostics (ASX:RAD) to develop innovative radiotherapy assets within the ASX 200 sector.
Percheron Therapeutics Advances Oncology Pipeline with Phase II
September 30, 2025 12:22 PM AEST| By SamPercheron Therapeutics advances its HMBD-002 oncology program, securing regulatory control and preparing Phase II trials, reflecting strategic growth within the ASX 200 biotech sector.
Navigating the Storm: How Trump's Pharma Tariffs Impact ASX Healthcare Stocks
September 29, 2025 10:46 PM AEST| By SamThis article delves into the implications of U.S. President Donald Trump's 100% tariff on imported branded and patented pharmaceuticals, effective October 1, 2025.
Cochlear’s Growth Story Sparks Spotlight in the ASX 200
September 29, 2025 03:10 PM AEST| By SamCochlear (ASX:COH) shows strong capital efficiency, sustainable growth, and reduced liability reliance, reinforcing its leadership in healthcare and highlighting its importance within the ASX 200 landscape.
PolyNovo (ASX:PNV) & Key Short Selling Market Trends
September 29, 2025 11:02 AM AEST| By SamThis article delves into the dynamics of short selling in the Australian stock market, focusing on PolyNovo Limited (ASX:PNV) and its recent market movements.
CSL in Focus: What the ASX 200 Signals About Growth
September 26, 2025 03:33 PM AEST| By SamCSL Limited (ASX:CSL) draws attention in the ASX 200, with valuation debates, steady earnings growth, and contrasting market sentiment shaping its outlook within Australia’s healthcare and stock market landscape.
Tariffs Pressure CSL as ASX 200 Edges Lower
September 26, 2025 03:04 PM AEST| By SamAustralian market edged lower as (ASX:CSL) fell on US tariff news, with technology weakness weighing while ASX mining stocks and ASX dividend stocks showed resilience.
Health Stocks Face Pressure Amid ASX 200 Pharma Tariff Clouds
September 26, 2025 02:44 PM AEST| By SamHealth and retail stocks face pressure as CSL (ASX:CSL) responds to US pharma tariffs while Premier Investments (ASX:PMV) battles Smiggle misconduct concerns, sparking caution across the broader ASX market.
CSL (ASX:CSL) US Tariff Impact: Key Insights for ASX 200 Investors
September 26, 2025 01:48 PM AEST| By SamCSL (ASX:CSL) faces challenges as US tariffs on pharmaceuticals impact profits, influencing ASX 200 biotech investors and short selling trends in Australia.
INOVIQ (ASX: IIQ) Advances Ovarian Cancer Detection, Gaining Spotlight in ASX 200 Landscape
September 26, 2025 12:16 PM AEST| By SamINOVIQ (ASX:IIQ) secures worldwide rights for novel ovarian cancer biomarker technology, advancing its EXO-OC test in early cancer detection and shaping the ASX 200 healthcare landscape.
Advertise your brand on Kalkine Media